Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

26-01-2024(Fri) 25-01-2024(Thu) 24-01-2024(Wed) 23-01-2024(Tue) 22-01-2024(Mon)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
24 Oct, 2019 (Thursday)



CHINA TOWER(788)
Analysis¡G
China Tower`s 19H1 revenue reached RMB 37.98 billion, up 7.5% yoy; net profit increased by 110.6% yoy to RMB 2.55 billion. Domestic mobile phone manufacturers such as Huawei and Xiaomi have said that they will launch new mobile phones soon. The 5G landing time is getting closer and closer, and the demand for base station construction will increase accordingly. As of the end of July, the company has completed the construction and delivery of 7863 5G base stations, and the operators have opened 6324 5G base stations. It is expected that by the end of 2019, more than 10,000 5G base stations will be built.
Strategy¡G
Buy-in Price: $1.65, Target Price: $2.30, Cut Loss Price: $1.32


Sawai Pharmaceutical Co., Ltd (4555)
Established in 1948. A leading manufacturer of generic drugs. Manufactures and sells nonprescription drugs and about 700 types of ethical drugs such as therapeutic agents for lifestylerelated illness (hypertension, dyslipidemia, diabetes etc) and anti-cancer drugs etc.For 1Q (Apr-Jun) results of FY2020/3 announced on 6/8, revenue increased by 4.1% to 47.134 billion yen compared to the same period the previous year, and core operating profit, excluding profit and loss due to non-recurring factors, increased by 18.7% to 10.646 billion yen. While sales and profits in the US had declined due to a decline in generic drug prices, those for Japan had increased due to strong sales in hospitals and pharmacies.For its full year plan, revenue is expected to remain at 184.4 billion yen compared to the previous year, core operating profit to decrease by 15.2% to 32.0 billion yen, and current income to decrease by 0.9% to 19.2 billion yen. Company is expected to face serious challenges, such as drug price revision in Japan due to the consumption tax increase, and the oligopoly of wholesalers and pharmacies in the US as well as the increase in the number of ¡§Abbreviated New Drug Applications (ANDA)¡¨. With the flu season in Japan beginning two months earlier than usual, outlook for the company, which deals with generic drugs for Tamiflu, looks good.Target Price : 6,000 yenBuy Price : 5,300 yenCut-Loss : 5,120 yen



Mengniu (2319.HK) - Acquisition of Bellamy helping milk powder business development; maintaining whole financial year's guidelines

Investment Summary

Mengniu announced that it intends to acquire Bellamy's Australia at a price of no more than AUD1.46 billion (HKD7.86 billion), with a planned share of AUD12.65 per share. Bellamy's net profit after tax is AUD21.7 million in FY2019. The P/E ratio is 67 times. Bellamy is Australia's first organic milk powder brand. It is listed on the ASX. It is a global recognised brand and has operations in Australia, New Zealand, China and Southeast Asia.We believe that the acquisition will be highly complementary to Mengniu's existing infant formula business, which will help Mengniu expand China and overseas markets. Organic IMF enjoys significantly faster growth and higher margins compared to the overall IMF market. Bellamy's gross profit margin of FY 2019 reached 43.5%, and the EBITDA rate reached 17.6%, both higher than Mengniu. Bellamy's FY 2018/2019 revenue fell 19% y.o.y. to AUD266 million, mainly due to the slower-than-expected approval of China's milk powder formula registration, and the e-commerce law. Mengniu said that after the acquisition, it will closely communicate with the relevant departments to assist Bellamy to accelerate the registration approval.

Mengniu's revenue in 1H of FY2019 increased by 15.6% y.o.y., if excluding Junlebao, the growth rate was 13%. Up to 9.5% of revenue growth came from sales volume growth, and the rest was the increase in ASP, mainly due to faster growth of basic products. The management team still maintains the guidance of the whole year, with low double-digit growth in revenue (including Junlebao, which will be finished disposal in 2H. Operating profit margin improved by 50 points in 1H and is expected to be maintained in 2H. Gross profit margin decreased by 0.1 ppt y.o.y. to 39.1%, while GPM was flat excluding Junlebao. Raw milk price rose by 5 to 6%, higher than management team's expectation. But thanked for the product mix optimization, the high-end milk business is growing rapidly. The prices of other raw materials fell, and the tax rate has also had a positive impact, which led to an improvement in operating profit margins.

After the announcement of the interim results, the stock price was under pressure. The market worried that the price of raw milk would remain high, and the market competition continued, which put pressure on operating profit. We believe the increase of raw milk price will help the performance of Modern Dairy (1117.hk) to resume. Mengniu's product mix will continue to be optimized, and it is expected that GPM can be maintained. After the completion of the disposal of Junlebao, profit margin can be improved. In 1H, the liquid milk business, which accounted for 83% of total revenue, increased by 14.4% y.o.y., the milk powder business increased by 43.8%, and ice cream decreased by 2.4%. For the liquid milk business, the market share of UHT products and chilled yogurt increased compared with the same period of last year. The former increased by 0.5 ppt to 28.5%, and continued to rank the second in the market. The latter increased by 1.3 ppt to 34.5%, and continued to be the market leader. For the e-commerce liquid milk category, the market share increased by 0.9 ppt to 24.6%, which also ranked the first in the market.

During the period, the income of Milk Deluxe and Just Yoghurt which belong to the room temperature product business increased by 20% and 24% respectively, and Fruit Milk Drink also recorded double-digit growth, while the basic white milk business increased by 19%. During the period, Milk Deluxe had been launched fully revamped packaging, Just Yoghurt had been launched new flavor products, Fruit Milk Drink had been launched high-end products. The chilled product business has also introduced new packaging and a variety of new products. We give a forecast PE of 31 times and target price of HKD34.6. (current price as of 21st October, 2019)

Valuation and risk

We are optimistic about the industry and the company's prospects, thus give forecast PE ratio of 31 times and target price of HKD34.6. Potential risks include failure to meet revenue growth, lower profit margins than expected, and huge fluctuations in raw milk prices. (current price as of 21st October 2019)

Financials

Click Here for PDF format...




Recommendation on 24-10-2019
RecommendationAccumulate
Price on Recommendation Date$ 31.200
Suggested purchase priceN/A
Target Price$ 34.600
Writer Info
Tracy Ku
(Research Analyst)
Tel: +852 2277 6516
Email:
tracyku@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]